FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 8, 2020--
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the pricing of its public offering of 2,400,000 shares of its common stock at a price to the public of $20.00 per share. The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $48.0 million.
In addition, Mirum has granted the underwriters a 30-day option to purchase up to an additional 360,000 shares of common stock at the public offering price less underwriting discounts and commissions. The offering is expected to close on January 13, 2020, subject to satisfaction of customary closing conditions.
Citigroup, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. Raymond James is acting as lead manager. Roth Capital Partners is acting as co-manager.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at (800) 831-9146; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by email at email@example.com or by phone at (888) 474-0200.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on January 8, 2020. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005918/en/
Source: Mirum Pharmaceuticals, Inc.
Heidi Chokeir, Ph.D.
Ian Clements, Ph.D.